- Inspira Technologies (IINN, Financial) generates initial revenues from FDA-cleared INSPIRA ART100 systems.
- First deployment at a leading U.S. academic medical center, with plans for expansion.
- Revenue reached the low hundreds of thousands of dollars, marking a critical commercialization milestone.
Inspira Technologies (NASDAQ: IINN) has reported its first revenue generation from the deployment of its FDA-cleared INSPIRA ART100 systems. This achievement is a significant milestone in the company’s commercial journey, marking its entry into the U.S. healthcare market. The initial revenues were generated through a successful installation at a premier U.S. academic medical center, and are reported to be in the low hundreds of thousands of dollars.
Inspired by the success of their initial deployment, the company has announced plans to expand their technology to a second leading academic medical center. The INSPIRA ART100 system is designed for cardiopulmonary bypass procedures, playing a crucial role in circulating and oxygenating blood outside the body during cardiac surgeries. This advancement not only boosts the company’s current market positioning but also lays the foundation for the future development of the INSPIRA ART500 system.
The INSPIRA ART500, currently under development, aims to address the $19 billion mechanical ventilation market. It is designed to provide direct blood oxygenation for patients with respiratory failure without the need for mechanical ventilation, thus allowing patients to remain awake during treatment. This approach promises a safer alternative to traditional mechanical ventilation, particularly significant in light of recent respiratory health crises.
"Generating our first revenues represents a transformative milestone for Inspira as we establish our presence in the U.S. medical landscape," commented Dagi Ben-Noon, Chief Executive Officer of Inspira. The company continues its strategic expansion by collaborating with additional leading medical experts and institutions to validate its innovative approach to extracorporeal life support.
